exicuretx.com - מכפיל P/S עתידי XCUR

Exicure, Inc. (XCUR) faces a critical funding shortage and the threat of delisting in the absence of new investments. On GURU.Markets, the projected market cap-to-revenue ratio, where 70.90 represents the current metric level, demonstrates the potential of RNA-based oncology drugs. The company is currently urgently restructuring its R&D pipeline, developing targeted SNA products to overcome the stagnation in clinical trials.

Downsizing the workforce to a compact scientific core and transitioning to external contracts minimize costs for Exicure, Inc. (XCUR), focusing capital on development. The ratio of current market capitalization to projected revenue allows for an assessment of market expectations for future sales; therefore, analyzing the company's projected P/S chart helps investors recognize asset overvaluation in a timely manner and avoid buying at local peaks.